Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-08
2008-04-08
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S125000, C544S361000, C546S051000, C514S253030, C514S283000
Reexamination Certificate
active
11581950
ABSTRACT:
The invention relates to novel derivatives of 14,15-dihydro 20,21-dinoreburnamenin-14-ol, having formula (I)in which R represents a radical —AR′ wherein A represents a heteroatom and R′ represents a group selected from the group comprising linear or branched C1-C6alkyl radicals, C2-C6alkenyls, C2-C6alkynyls, arylalkyls; esters comprising the formula —R1— CO—O—R2; amides comprising the formula —R3—CO—NZY, wherein Y and Z together can form a cycloalkyl radical or a heterocyclic radical, optionally substituted by one or more alkyl radicals; a radical selected from the group comprising alkyl radicals, alkenyls or alkynyls, substituted by at least one amine with formula —NZY; or one of the pharmaceutically-acceptable salts thereof, including the isomers, enantiomers and diastereoisomers thereof and mixtures thereof. The invention also relates to the use of the novel derivatives for the preparation of a pharmaceutical composition which is intended, in particular, for the treatment and/or prevention of depression, sleep-wake cycle disorders and symptomatic frontal disorders in cognitive components among humans.
REFERENCES:
patent: 3755335 (1973-08-01), Thai et al.
patent: 3937709 (1976-02-01), Sevenet et al.
patent: 4011330 (1977-03-01), Guidicelli et al.
patent: 4057550 (1977-11-01), Szantay et al.
patent: 4291038 (1981-09-01), Farcilli et al.
patent: 5034396 (1991-07-01), Aktogu et al.
patent: 0 317 426 (1989-05-01), None
patent: 0 317 427 (1989-05-01), None
patent: 2 190 113 (1974-01-01), None
patent: 2 285 882 (1976-04-01), None
patent: 2 312 245 (1976-12-01), None
patent: 2 433 528 (1977-02-01), None
patent: 2 381 048 (1978-09-01), None
patent: WO 89/04830 (1989-06-01), None
Ginovart N, Marcel D, Bezin L, Garcia C, Gagne C, Pujol JF, Weissmann D., “Tyrosine hydroxylase expression within Balb/c and C57black/6 mouse locus coeruleus. I. Topological organisation and phenotypic plasticity of the enzyme-containing cell population”, Brain Res. May 20, 1996; 721 (1-2): 11-21.
Ginovart N, Marcel D, Bezin L, Gagne C, Pujol JF, Weissmann D., “Tyrosine hydrolaxylase expression within Balb/c and C57black/6 mouse locus coeruleus. II. Quantitative study of the enzyme level”, Brain Res. May 6, 1996; 719(1-2): 45-55.
Weissmann D, Labatut R, Richard F, Rousset C, Pujol JF, “Direct transfer into nitrocellulose and quantitative radioautographic anatomical determination of brain tyrosine hydroxylase protein concentration”, J. Neurochem. Sep. 1989; 53 (3): 793-9.
Bourde O., Schmitt P and Pujol JF, “Long-term effect of RU24722 on tyrosine hydroxylase protein concentration on the locus coeruleus of mice: Differential results in Balb/c, C57BL/6 and their CB6 F1 hybrid”, Neurochem Int. 1991, 19, (1), 25-31.
Labatut R, Richard F, Milne B, Quntin L, Lecestre D, Pujol JF. “Long-term effects of RU24722 on tyrosine hydroxylase of the rat brain”, J. Neurochem. Nov. 1988; 51(5):1367-74.
Schmitt P, Reny-Palasse V, Bourde O, Garcia C, Pujol JF, “Further characterisation of the long-term effect of RU24722 on tyrosine hydroxylase in the rat locus coeruleus”, J. Neurochem. Oct. 1993; 61(4): 1423-9.
X. Liu and H.K. Gershenfeld, “Genetic Differences in the Tail-Suspension Test and Its Relationship to Imipramine Response among 11 Inbred Strains of Mice”, Biol. Psychiatry 2001 49, 575-581.
J.S. Allard Y Tizabio, JP Shaffery, C.O. Trouth, K. Manabe, “Stereological analysis of hypothalamic hypocretin/orexin neurons in animal models of depression”, Neuropeptides 2004, 38, 311-315.
D. Chabas, S. Taheri, C. Renier, and E. Mignot, “The genetic narcolepsie”, An Rev. Genomics Human Genet. 2003, 4, 459-83.
Arango V, Underwood MD, Mann J., “Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results”, Biol Psychiatry 1996, 39 112-120.
Mann J.J., “Neurobiology of suicidal behavior”, Nature Reviews/Neuroscience 4, 2003, 820-28.
Marc R. Mariena, Francis C. Colpaerta, Alan C. Rosenquist, “Noradrenergic mechanisms in neurodegenerative diseases: a theory”, Brain Research Reviews 45 (2004) 38-78.
M. Gesi, P. Soldani, F-S Giorgi, A. Santinami, I. Bonaccorsi and F. Fornai, “The role of the locus coeruleus in the development of Parkinson's disease”, Neuroscience & Biobehavioral Reviews, vol. 24, Issue 6, Aug. 2000, pp. 655-668.
Kettera T A and Drevets WC, Clinical Neuroscience Research 2 (2002) 182-192, “Neuroimaging studies of bipolar depression: functional neuropathology, treatment effects, and predictors of clinical response” Clinical Neuroscience Research 2 (2002) 182-192.
Ronald C. Petersen, “Mild cognitive impairment: clinical trials”, Nature reviews, Drug Discovery vol. 2, Aug. 2003 647.
Vjera A. Holthoff, Bettina Beuthien-Baumann, Elke Kalbe, Susanne Lüdecke, Olaf Lenz, Gerhard Zündorf, Sebastian Spirling, Kristin Schierz, Peter Winiecki, Sandro Sorbi and Karl Herholz, “Regional Cerebral Metabolismin Early Alzheimer's Disease with Clinically Significant Apathy or Depression”, Biol Psyschiatry 2005;57: 412-421.
Eve M. Valera, Stephen V. Faraone, Joseph Biederman, Russel A. Poldrack, and Larry J. Seidman, “Functional Neuroanatomy of Working Memory in Adults with Attention-Deficit/Hyperactivity Disorder”, Biol Psychiatry 2005;57: 439-447.
J.D. Cohen R. Ganguli C. Carter J. Brar T Nichols M. DeLeo M. Mintun, “Hypofrontality and working memory dysfunction in schizophrenia”, Biological Psychiatry, vol. 37, Issue 9, May 1, 1995, p. 633.
The fourth edition of the Diagnostic and Statistical Manual of mental Disorder-American Psychiatric Association Publisher. Washington DC.
Fava M, Davidson KG., “Definition and epidemiology of treatment-resistant depression”, Psychiatry Clin North Am. Jun. 1996; 19(2): 179-200.
Lancet, “Efficacy and Safety of Electroconvulsive Therapy in Depression Disorders: A Systematic Review and meta-Analysis”, The UK ECT Review Group, Mar. 8, 2003, The Lancet, vol. 361, pp. 799-808.
Couturier J.L., “Efficacy of Rapid-Rate Repetitive Transcranial Magnetic Stimulation in the Treatment of Depression: A Systematic Review and Meta-Analysis”, J. Psychiatry Neurosci., Mar. 2005, 30(2), pp. 83-90.
Sackeim, H.A. et al., “Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression: Efficacy, Side Effects, and Predictors of Outcome”, Neuropsychopharmacology 2001, vol. 25, No. 5; pp. 25, 713-728.
Mayberg, H.S., et al., “Deep Brain Stimulation for Treatment-Resistant Depression”, Neuron, vol. 45, pp. 651-660, Mar. 2005.
Ciapetti Paola
Deyon Laurence
Pujol Jean-François
Weissmann Dinah
Wermuth Camille-Georges
Aulakh Charanjit S.
Biocortech
Dorsey & Whitney LLP
Rothenberger Scott D.
LandOfFree
Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3930312